Search

Corvus Pharmaceuticals Inc

Open

12.54 -6.7

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

12.21

Max

13.45

Schlüsselkennzahlen

By Trading Economics

Einkommen

-4.3M

-18M

EPS

-0.19

Angestellte

37

EBITDA

-5.3M

-17M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+119.49% upside

Dividenden

By Acuity

Nächstes Ergebnis

3. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-80M

1B

Vorheriger Eröffnungskurs

19.24

Vorheriger Schlusskurs

12.54

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

22. Sept. 2026, 23:56 UTC

Correlated Moves

TE Connectivity PLC declined slightly in after-market trading, amid concerns over economic momentum following a drop in the Richmond Fed Manufacturing Index.

22. Sept. 2026, 23:56 UTC

Raymond James Financial Inc is trading modestly lower in after-market hours, continuing a decline since Tuesday and remaining near the low end of its one-month range.

22. Sept. 2026, 23:56 UTC

Correlated Moves

Hess Midstream LP is trading lower in after-market hours, following a flat session and amid a decline in shares of Targa Resources Corp.

22. Sept. 2026, 23:56 UTC

Correlated Moves

Agree Realty Corp is trading slightly higher in after-market hours, influenced by positive earnings reports from consumer discretionary companies.

22. Sept. 2026, 23:56 UTC

Plumas Bancorp remains roughly flat in after-market trading, showing little change since Tuesday's close and oscillating around the midpoint of its one-month trading range.

22. Sept. 2026, 23:56 UTC

Correlated Moves

Delek US Holdings Inc is trading lower in after-market hours, potentially in sympathy with HF Sinclair Corp, which has also declined.

22. Sept. 2026, 23:55 UTC

Andersons Inc is experiencing notable gains in after-market trading, recovering from previous lower closes but remains below its 20-day moving average.

22. Sept. 2026, 23:55 UTC

Pentair PLC is trading modestly higher in after-market hours, continuing a gradual increase, though it remains below its 20-day moving average.

22. Sept. 2026, 23:55 UTC

Healthequity Inc. is trading modestly lower in after-market hours, continuing a decline from Tuesday's close and remaining below its 20-day moving average.

22. Sept. 2026, 23:55 UTC

M&T Bank Corp is trading modestly higher in after-market hours, remaining above its opening level despite a slight pullback during the regular session.

22. Sept. 2026, 23:55 UTC

Darling Ingredients Inc is trading modestly lower in after-market hours, continuing a four-session decline and remaining significantly below its 20-day moving average.

22. Sept. 2026, 23:55 UTC

News

Roivant Sciences Ltd is higher in after-market trading following positive Phase 2 trial results for mosliciguat, showing significant improvements in pulmonary hypertension patients.

22. Sept. 2026, 23:52 UTC

CarMax Inc. is trading modestly lower in after-market hours, continuing a decline since Tuesday's close and remaining below its 20-day moving average.

22. Sept. 2026, 23:51 UTC

News

Itron Inc's stock is declining in after-market trading, despite the launch of its Riva IEC Grid Edge Portfolio in the Asia Pacific region.

22. Sept. 2026, 23:51 UTC

MACOM Technology Solutions Holdings Inc is up in after-market trading, continuing a trend of seven consecutive higher daily closes and remaining above its 20-day moving average.

22. Sept. 2026, 23:51 UTC

Old Dominion Freight Line Inc is trading modestly lower in after-market hours, remaining significantly below its 20-day moving average after a brief rise earlier.

22. Sept. 2026, 23:51 UTC

First Solar Inc is trading modestly lower in after-market hours, following a notable dip earlier in the session and remaining below its 20-day moving average.

22. Sept. 2026, 23:51 UTC

Eversource Energy is trading modestly higher in after-market hours, despite recent lower performance and positioning below its 20-day moving average.

22. Sept. 2026, 23:51 UTC

Nucor Corp is trading modestly lower in after-market hours, continuing a downward trend since Tuesday's close and positioned below its 20-day moving average.

22. Sept. 2026, 23:51 UTC

Targa Resources Corp is seeing a modest decline in after-market trading, continuing a trend of three consecutive lower daily closes.

22. Sept. 2026, 23:51 UTC

Correlated Moves

SM Energy Co is trading modestly lower in after-market hours, continuing a decline amid concerns from the Richmond Fed Manufacturing Index's unexpected fall.

22. Sept. 2026, 23:51 UTC

Brazil's Unemployment Rate Set to Release on September 29, Expected to Reflect Continued Labor Market Improvement Amid Global Economic Concerns.

22. Sept. 2026, 23:51 UTC

Australia's S&P Global Services PMI at 51.4 signals slight expansion, but mixed retail forecasts raise concerns about consumer spending ahead of the holiday season.

22. Sept. 2026, 23:51 UTC

Australia's S&P Global Manufacturing PMI Flash at 49.3 Signals Contraction, Raising Concerns Over Economic Growth and Potential Monetary Policy Adjustments.

22. Sept. 2026, 23:51 UTC

Japan's Industrial Production Report Set for Release on September 29, Amidst Positive Trends and Global Economic Influences.

22. Sept. 2026, 23:51 UTC

Japan's Retail Sales Data Release on September 29 Faces Caution Amid Interest Rate Hike and Yen Weakness.

22. Sept. 2026, 23:50 UTC

News

Coeur Mining plans a record $158 million exploration investment for 2026, more than double 2025's budget, as shares rise in after-market trading.

22. Sept. 2026, 23:50 UTC

Cinemark Holdings Inc is declining in after-market trading, falling from earlier gains and nearing the lower end of its one-month trading range.

22. Sept. 2026, 23:50 UTC

Veeva Systems Inc is trading modestly higher in after-hours action, remaining below its 20-day moving average and around the midpoint of its one-month range.

22. Sept. 2026, 23:50 UTC

Aspen Aerogels Inc is trading lower in after-market hours, showing a significant decline from Tuesday's close, though still above its 20-day moving average.

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

119.49% Vorteil

12-Monats-Prognose

Durchschnitt 29.5 USD  119.49%

Hoch 33 USD

Tief 27 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

4

Buy

0

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.